THE skin microbiome may shape aging through barrier, immune, and metabolic pathways, but causality remains unproven.
The skin microbiome forms part of a complex cutaneous ecosystem that supports barrier integrity, immune regulation, and metabolic homeostasis. A new review places age-associated microbial changes within the wider physiology of aging skin, including reduced sebaceous activity, altered hydration and surface pH, slower barrier recovery, oxidative stress, chronic low-grade inflammation, and extracellular matrix deterioration.
These physiological changes can modify the ecological conditions that determine which microorganisms colonize different skin sites. Sebaceous, moist, and dry regions each support distinct microbial communities, while anatomy, environmental exposures, hygiene practices, and cosmetic use contribute additional variation.
Changes involving Cutibacterium, Corynebacterium, Staphylococcus, and Malassezia may therefore act as indicators of an altered cutaneous environment rather than independent causes of skin aging.
The review emphasizes that identifying a microorganism does not establish what it is doing or how it affects the host. Biological effects depend on strain-specific genes, pathway activity, available substrates, and the production of metabolites.
Skin microorganisms can process host lipids and amino acids to produce free fatty acids, short-chain fatty acids, ceramides, and tryptophan-derived compounds. These products may contribute to surface acidity, epidermal differentiation, barrier repair, antimicrobial defense, and immune signaling.
Microbial ligands and metabolites may also influence inflammatory and metabolic pathways associated with aging. However, human evidence has not demonstrated that age-associated microbiome changes directly initiate cellular senescence, mitochondrial dysfunction, or dermal matrix degradation.
Microbiome-compatible skin care, prebiotics, postbiotics, live biotherapeutic products, bacteriophages, and strategies supporting microbial recovery after dermatologic procedures are under investigation. Early trials show that microbial abundance can sometimes be modified safely, but these changes do not necessarily improve clinical disease severity.
For physicians, current microbiome findings should not yet guide routine treatment selection. Research is limited by small and cross-sectional cohorts, low microbial biomass, contamination risk, anatomical variation, and inconsistent sampling and sequencing methods.
Longitudinal studies integrating strain-level data, microbial gene expression, metabolites, host responses, and clinical phenotypes will be needed to determine whether microbial remodeling causes, follows, or simply accompanies cutaneous aging.
Reference
Bautista J et al. Skin microbiome and cutaneous aging mechanisms and clinical implications. Front Microbiol. 2026;17:1917816. doi:10.3389/fmicb.2026.1917816.
Featured Image: Marco on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
